AUG 14·SEC EDGARLow
Lee Chan Henry sold $960K of ONC
Lee Chan Henry (SVP, General Counsel) sold 2,666 shares of BeOne Medicines Ltd. (ONC) at $360.00 ($0.96M total) on 2026-08-11 under a Rule 10b5-1 trading plan.
StockNASDAQ · US · USDHealthcare · Biotechnology
$ONC
BeOne Medicines Ltd.
Price · $ONCvia TradingView
AI sentiment · 7d3 articles
- Bullish
- 2
- Neutral
- 1
- Bearish
- 0
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $232.8M 68 txs
OYLER JOHN64× · $230.6M
10b5-1 share of filings97%
Top stories · $ONCMore →
AUG 12·SEC EDGAR
OYLER JOHN sold $86.5M of ONC
OYLER JOHN (Chief Executive Officer) sold 240,810 shares of BeOne Medicines Ltd. (ONC) at an average of $359.12 ($350.00–$367.00, $86.48M total) across 24 trades over 2026-08-10 to 2026-08-12 under a Rule 10b5-1 trading plan.
AUG 12·fool.com
BeOne Medicines (ONC) Q2 2026 Earnings Call Transcript
BeOne Medicines (ONC) reported Q2 2026 revenue of $1.7B, up 30%, and GAAP diluted EPS of $2.05, up 144%. BRUKINSA revenue was $1.2B. Full-year 2026 guidance was raised to $6.6B-$6.8B revenue and $1.0B-$1.1B GAAP operating income. Management cited Phase III MANGROVE and real-world Medicare data.
ONC sentiment & insider activity
Over the past 7 days, alphai's AI scored 3 news stories mentioning ONC (BeOne Medicines Ltd.). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent ONC coverage spans insider activity, earnings and financial news.
In the last 30 days, ONC insiders filed 68 SEC Form 4 transactions — no purchases and 68 sales ($232.8M). The most active reporter was OYLER JOHN, Chief Executive Officer, with 64 filings. 97% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving ONC
The filing is a routine insider sale under a 10b5-1 plan, with no new operational or financial catalyst disclosed.
Large CEO open-market sale under a 10b5-1 plan can modestly pressure sentiment, but it is not a fundamental operational update by itself.
Guidance raise plus new Phase III and real-world survival data supports a bullish re-rate, but the zanubrutinib sonrotoclax uMRD miss adds execution risk.
A planned Rule 144 insider-related sale can add near-term supply overhang, but the filing alone does not signal fundamentals.
The deal expands ONC’s regional commercialization runway and adds a funded global Phase 3 registrational study for one RAS(ON) inhibitor.
alphai scores every news story that mentions ONC with an AI model for sentiment and relevance, and aggregates insider trades from BeOne Medicines Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $ONC
Score
Lee Chan Henry sold $960K of ONC
Lee Chan Henry (SVP, General Counsel) sold 2,666 shares of BeOne Medicines Ltd. (ONC) at $360.00 ($0.96M total) on 2026-08-11 under a Rule 10b5-1 trading plan.
2 min readOYLER JOHN sold $86.5M of ONC
OYLER JOHN (Chief Executive Officer) sold 240,810 shares of BeOne Medicines Ltd. (ONC) at an average of $359.12 ($350.00–$367.00, $86.48M total) across 24 trades over 2026-08-10 to 2026-08-12 under a Rule 10b5-1 trading plan.
2 min read
BeOne Medicines (ONC) Q2 2026 Earnings Call Transcript
BeOne Medicines (ONC) reported Q2 2026 revenue of $1.7B, up 30%, and GAAP diluted EPS of $2.05, up 144%. BRUKINSA revenue was $1.2B. Full-year 2026 guidance was raised to $6.6B-$6.8B revenue and $1.0B-$1.1B GAAP operating income. Management cited Phase III MANGROVE and real-world Medicare data.
7 min readOncosec (ONC) filer Chan Lee plans Rule 144 sale of 718,718 ADS
Chan Lee, an Oncosec Medical Incorporated (ONC) filer, submitted a Rule 144 notice to sell 718,718 American Depositary Shares (ADS) on NASDAQ. The ADS were acquired in 2002 and are linked to stock option exercises for cash. The sale is set to occur via Morgan Stanley Smith Barney LLC, with an event date of 08/11/2026.
2 min read
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
BeOne Medicines (Nasdaq: ONC) and Revolution Medicines (Nasdaq: RVMD) announced a clinical collaboration to test combinations of BeOne oncology assets with Revolution’s four RAS(ON) inhibitors (daraxonrasib, zoldonrasib, elironrasib, RMC-5127). BeOne also received exclusive development and commercialization rights for these assets in select Asian markets, with milestones and tiered royalties. BeOne will fund a global Phase 3 registrational study for one inhibitor.
4 min readRosenberg Aaron sold $362K of ONC
Rosenberg Aaron (Chief Financial Officer) sold 1,157 shares of BeOne Medicines Ltd. (ONC) at $312.72 ($0.36M total) on 2026-08-03.
2 min read
BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates
BeOne Medicines (NASDAQ: ONC) reported Q2 2026 revenue of $1.7B, up 30% y/y, led by BRUKINSA sales of $1.2B (+31%). GAAP diluted EPS was $2.05 per ADS and non-GAAP diluted EPS $3.84. The company raised 2026 revenue guidance to $6.6B-$6.8B and forecast high-80% gross margin, plus updated operating income ranges.
6 min readBeOne Medicines Ltd. (ONC): Results of Operations and Financial Condition
BeOne Medicines Ltd. (ONC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-q22026earningsr.htm EX-99.1 Document Exhibit 99.1 BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates • Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year • BRUKINSA (zanubruti
6 min read
BeOne Committing $1 Billion+ To U.S. Drug Manufacturing Growth
BeOne Medicines (Nasdaq: ONC) said it will invest $300 million to expand its Princeton West Innovation Campus in Hopewell, New Jersey, adding small molecule manufacturing capacity. The expansion brings total U.S. investment to over $1 billion, creates about 120 jobs, adds 145,000 sq ft, and is expected to be fully operational in 2029.
4 min readLee Chan Henry sold $338K of ONC
Lee Chan Henry (SVP, General Counsel) sold 1,044 shares of BeOne Medicines Ltd. (ONC) at $323.69 ($0.34M total) on 2026-07-30.
1 min read